You need JavaScript to view this

Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer

Abstract

Introduction. In patients with advanced ovarian cancer undergoing preoperative PET/CT, we investigated the prognostic value of SUV in the primary tumor and we evaluated the value of SUV for predicting incomplete primary cytoreduction (macroscopic residual tumor). Material and methods. From September 2004 to August 2007, 201 consecutive patients with a pelvic tumor and a Risk of Malignancy Index (RMI) > 150 based on serum CA-125, ultrasound examinations and menopausal state, underwent PET/CT within two weeks prior to standard surgery/debulking of a pelvic tumor. At two-year follow-up (August 15, 2009) the association between SUV and overall survival/cytoreductive result were analyzed in 60 ovarian cancer patients (58 stage III and two stage IV). Results. At inclusion median age was 62 years (range 35-85 years); 97% (58/60) had a performance status <=2; 42% (25/60) underwent complete debulking (no macroscopic residual tumor); median SUV{sub max} was 13.5 (range 2.5-39.0). Median follow-up was 30.2 months. At follow-up 57% (34/60) were alive and 43% (26/60) had died from ovarian cancer. SUV{sub max} in patients alive was not statistically different from SUV{sub max} in dead patients (p=0.69), and SUV{sub max} was not correlated with the amount of residual tumor after surgery (p=0.19). Using univariate Cox regression analysis,  More>>
Authors:
Risum, Signe; Engelholm, Svend A. (Dept. of Oncology, the Finsen Center, Rigshospitalet, Copenhagen Univ. Hospital (Denmark)), email: signerisum@hotmail.com; Loft, Annika; Berthelsen, Anne K; [1]  Hoegdall, Claus; Lundvall, Lene; [2]  Hoegdall, Estrid; [3]  Nedergaard, Lotte [4] 
  1. PET and Cyclotron Unit, Dept. of Clinical Physiology and Nuclear Medicine, Centre of Diagnostic Investigations, Rigshospitalet, Copenhagen Univ. Hospital (Denmark)
  2. Gynecologic Clinic, the Juliane-Marie Center, Rigshospitalet, Copenhagen Univ. Hospital (Denmark)
  3. Dept. of Pathology, National Biobank, Herlev Hospital, Copenhagen Univ. Hospital (Denmark)
  4. Dept. of Pathology, Centre of Diagnostic Investigations, Rigshospitalet, Copenhagen Univ. Hospital (Denmark)
Publication Date:
Apr 15, 2011
Product Type:
Journal Article
Resource Relation:
Journal Name: Acta Oncologica (online); Journal Volume: 50; Journal Issue: 3; Other Information: 10.3109/0284186X.2010.500296
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; POSITRON COMPUTED TOMOGRAPHY; COMPUTERIZED TOMOGRAPHY; OVARIES; NEOPLASMS
OSTI ID:
1011600
Country of Origin:
Sweden
Language:
English
Other Identifying Numbers:
Journal ID: ISSN 1651-226X; TRN: SE1108077
Availability:
Available from DOI: http://dx.doi.org/10.3109/0284186X.2010.500296
Submitting Site:
SWDN
Size:
page(s) 415-419
Announcement Date:
Apr 25, 2011

Citation Formats

Risum, Signe, Engelholm, Svend A. (Dept. of Oncology, the Finsen Center, Rigshospitalet, Copenhagen Univ. Hospital (Denmark)), email: signerisum@hotmail.com, Loft, Annika, Berthelsen, Anne K, Hoegdall, Claus, Lundvall, Lene, Hoegdall, Estrid, and Nedergaard, Lotte. Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer. Sweden: N. p., 2011. Web. doi:10.3109/0284186X.2010.500296.
Risum, Signe, Engelholm, Svend A. (Dept. of Oncology, the Finsen Center, Rigshospitalet, Copenhagen Univ. Hospital (Denmark)), email: signerisum@hotmail.com, Loft, Annika, Berthelsen, Anne K, Hoegdall, Claus, Lundvall, Lene, Hoegdall, Estrid, & Nedergaard, Lotte. Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer. Sweden. doi:10.3109/0284186X.2010.500296.
Risum, Signe, Engelholm, Svend A. (Dept. of Oncology, the Finsen Center, Rigshospitalet, Copenhagen Univ. Hospital (Denmark)), email: signerisum@hotmail.com, Loft, Annika, Berthelsen, Anne K, Hoegdall, Claus, Lundvall, Lene, Hoegdall, Estrid, and Nedergaard, Lotte. 2011. "Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer." Sweden. doi:10.3109/0284186X.2010.500296. https://www.osti.gov/servlets/purl/10.3109/0284186X.2010.500296.
@misc{etde_1011600,
title = {Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer}
author = {Risum, Signe, Engelholm, Svend A. (Dept. of Oncology, the Finsen Center, Rigshospitalet, Copenhagen Univ. Hospital (Denmark)), email: signerisum@hotmail.com, Loft, Annika, Berthelsen, Anne K, Hoegdall, Claus, Lundvall, Lene, Hoegdall, Estrid, and Nedergaard, Lotte}
abstractNote = {Introduction. In patients with advanced ovarian cancer undergoing preoperative PET/CT, we investigated the prognostic value of SUV in the primary tumor and we evaluated the value of SUV for predicting incomplete primary cytoreduction (macroscopic residual tumor). Material and methods. From September 2004 to August 2007, 201 consecutive patients with a pelvic tumor and a Risk of Malignancy Index (RMI) > 150 based on serum CA-125, ultrasound examinations and menopausal state, underwent PET/CT within two weeks prior to standard surgery/debulking of a pelvic tumor. At two-year follow-up (August 15, 2009) the association between SUV and overall survival/cytoreductive result were analyzed in 60 ovarian cancer patients (58 stage III and two stage IV). Results. At inclusion median age was 62 years (range 35-85 years); 97% (58/60) had a performance status <=2; 42% (25/60) underwent complete debulking (no macroscopic residual tumor); median SUV{sub max} was 13.5 (range 2.5-39.0). Median follow-up was 30.2 months. At follow-up 57% (34/60) were alive and 43% (26/60) had died from ovarian cancer. SUV{sub max} in patients alive was not statistically different from SUV{sub max} in dead patients (p=0.69), and SUV{sub max} was not correlated with the amount of residual tumor after surgery (p=0.19). Using univariate Cox regression analysis, residual tumor was a significant prognostic variable (p=0.001); SUV{sub max} was not a statistically significant prognostic variable (p=0.86). Discussion. FDG uptake (SUV{sub max}) in the primary tumor of patients with advanced ovarian cancer was not a prognostic variable and the FDG uptake did not predict complete cytoreduction after primary surgery. Future prospective clinical trials will need to clarify if other PET tracers can serve as prognostic variables in ovarian cancer}
doi = {10.3109/0284186X.2010.500296}
journal = {Acta Oncologica (online)}
issue = {3}
volume = {50}
place = {Sweden}
year = {2011}
month = {Apr}
}